Miflonide®/Foradil® via Aerolizer® compared with other anti-inflammatory and anti-obstructive therapeutic regimens;Miflonide®/Foradil® via Aerolizer® im vergleich zu anderen antiinflammatorischen und antiobstruktiven therapieregimes

Pneumologie

Volumn 57, Issue 3, 2003, Pages 137-143

  Gessner, C ^a   Stenglein, S ^b   Brautigam M ^b   Muller A ^b   Schauer, J ^a  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b NOVARTIS PHARMA GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; FLUTICASONE; FORMOTEROL FUMARATE; MIFLONIDE; SALMETEROL; STEROID; BRONCHODILATING AGENT; ETHANOLAMINE DERIVATIVE; FORMOTEROL;

ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NEBULIZER; PATIENT; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PHYSICAL EXAMINATION; PHYSICIAN; PRIORITY JOURNAL; SIDE EFFECT; SYMPTOM; TRAINING; AEROSOL; BODY MASS; LUNG FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY;

ADRENERGIC BETA-AGONISTS; ADULT; AEROSOLS; ASTHMA; BODY MASS INDEX; BRONCHODILATOR AGENTS; BUDESONIDE; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; RESPIRATORY FUNCTION TESTS;

EID: 0037531234     PISSN: 09348387     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-37738     Document Type: Article

References (21)

1. Wettengel R, Berdel D, Hofmann D et al. [Recommendations for asthma therapy in children and adults]. Pneumologie 1998; 52 (11): 591-601
2. Barnes PJ. Clinical outcome of adding long-acting beta-agonists to inhaled corticosteroids. Respir Med 2001; 95 (Suppl B): S12-16
3. Greening AP, Ind PW, Northfield M et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group, Lancet 1994; 344 (8917): 219-224
4. Woolcock A, Lundback B, Ringdal N et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996; 153 (5): 1481-1488
5. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). Bmj 2000; 320 (7246): 1368-1373
6. 2-agonists and corticosteroids. Eur Respir J 2002; 19 (1): 182-191
7. Spoelstra FM, Postma DS, Hovenga H et al. Additive anti-inflammatory effect of formoterol and budesonide on human lung fibroblasts. Thorax 2002; 57 (3): 237-241
8. 2-agonist therapy in asthma. Am J Respir Crit Care Med 2001; 164 (6): 923-932
9. Barnes PJ. Effect of β-agonists on inflammatory cells. J Allergy Clin Immunol 1999; 104 (2 Pt 2): S10-17
10. 2-adrenergic receptor agonist formoterol reduces microvascular leakage by inhibiting endothelial gap formation. Am J Physiol 1994; 266 (4 Pt 1): L461-468
11. 2-adrenergic receptor transcription in human lung. Am J Physiol 1995; 268 (1 Pt 1): L41-46
12. Juniper EF, Guyatt GH, Ferrie PJ et al. Measuring quality of life in asthma. Am Rev Respir Dis 1993; 147 (4): 832-838
13. Klein JJ, van der Palen J, Uil SM et al. Benefit from the inclusion of self-treatment guidelines to a self-management programme for adults with asthma. Eur Respir J 2001; 17 (3): 386-394
14. Lehrer P, Feldman J, Giardino N et al. Psychological aspects of asthma. J Consult Clin Psychol 2002; 70 (3): 691-711
15. Nielsen KG, Skov M, Klug B et al. Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer. Eur Respir J 1997; 10 (9): 2105-2109
16. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers - implications for in vitro testing. J Aerosol Med 1993; 6 (2): 99-110
17. Chew NY, Chan HK. In vitro aerosol performance and dose uniformity between the Foradile Aerolizer and the Oxis Turbuhaler. J Aerosol Med 2001; 14 (4): 495-501
18. Eliraz A, Ramirez-Rivera A, Ferranti P et al. Similar efficacy following four weeks treatment of asthmatics with formoterol 12 micrograms b.d. delivered by two different dry powder inhalers: differences in inhaler handling. Int J Clin Pract 2001; 55 (3): 164-170
19. Lotvall J, Mellen A, Arvidsson P et al. Similar bronchodilation with formoterol delivered by aerolizer or turbuhaler. Can Respir J 1999; 6 (5): 412-416
20. Kottakis J, Cioppa GD, Creemers J et al. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can Respir J 2002; 9 (2): 107-115
21. Benhamou D, Cuvelier A, Muir JF et al. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). Respir Med 2001; 95 (10): 817-821